Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Branebrutinib - Bristol Myers Squibb

Drug Profile

Branebrutinib - Bristol Myers Squibb

Alternative Names: BMS 986195

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Anti-inflammatories; Antirheumatics; Indoles; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 05 Dec 2022 Bristol-Myers Squibb completes a phase II trial in Systemic lupus erythematosus Sjögren's syndrome and Rheumatoid arthritis in USA, Argentina, Belgium, France, Germany, Mexico, Netherlands, Poland, Spain and United Kingdom (PO) (NCT04186871)
  • 22 Aug 2022 Bristol-Myers Squibb completes a phase II trial in Atopic dermatitis in USA, Spain, Poland, Germany, Canada, Austria and Australia (PO) (NCT05014438) (EudraCT2020-004767-77)
  • 01 Jun 2022 Safety and pharmacokinetics data from a phase I trials in healthy volunteers were presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top